Breakthrough cancer drug could be astronomical in price – USA TODAY
|
Breakthrough cancer drug could be astronomical in price
USA TODAY The treatment, CTL019, belongs to a new class of medications called CAR T-cell therapies, which involve harvesting patients’ immune cells and genetically altering them to kill cancer. It’s been tested in patients whose leukemia has relapsed in spite of … |
|
Stem Cell Therapy for Infections by Resilient Bacteria
Financial Tribune “Sometimes ulcers which are resistant to conventional treatment, respond positively and swiftly to stem cell treatments,” he explained, adding that officials from Council for Stem Cell Sciences and Technologies (affiliated to Vice-Presidency for … |
|
Doctor on new cancer treatment: ‘genetically engineered, tumor-killing factory’
The Business Journal CTL019, a CAR T-cell therapy from the pharmaceutical company Novartis, was recommended unanimously last month, and doctors in the Central Valley have taken notice. One person to welcome the therapy is Saint Agnes Cancer Center oncologist Dr. Ravi … |
|
Doctor on new cancer treatment: ‘genetically engineered, tumor-killing factory’
The Business Journal CTL019, a CAR T-cell therapy from the pharmaceutical company Novartis, was recommended unanimously last month, and doctors in the Central Valley have taken notice. One person to welcome the therapy is Saint Agnes Cancer Center oncologist Dr. Ravi … |
|
Jennifer Doudna, Feng Zhang Awarded NHGRI Grants for CRISPR-Based Research
GenomeWeb NEW YORK (GenomeWeb) – Jennifer Doudna and Feng Zhang have received separate grants from the National Human Genome Research Institute for CRISPR technology-based projects they both say have the potential to advance the tool’s usefulness for … |
|
New report proposes framework to identify vulnerabilities posed by synthetic biology
DeathRattleSports.com WASHINGTON – Given the possible security vulnerabilities related to developments in synthetic biology – a field that uses technologies to modify or create organisms or biological components – a new report by the National Academies of Sciences, … |
|
Licensed To Kill: Engineering Enzymes to Counter Antibiotic Resistance
DVIDS (press release) An effort funded by the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department and led by William Bentley, Ph.D., from the University of Maryland (UMD), is utilizing synthetic biology to engineer a probiotic to fight … |